Tharimmune (THAR)

Executive Summary

Tharimmune (NASDAQ: THAR) is a clinical-stage biotechnology company developing a transmucosal buccal film platform for drug delivery, with a lead candidate nalmefene for chronic pruritus associated with primary biliary cholangitis (PBC). The company completed a Phase 1 healthy volunteer study (NCT06198686) and is currently recruiting a Phase 2 trial (NCT06733519) evaluating nalmefene plus placebo in PBC patients with pruritus, with completion expected by June 2027. Tharimmune also explores blockchain applications for financial markets, though its primary focus remains on advancing its therapeutic pipeline. The company's buccal film technology offers a novel administration route, potentially addressing significant unmet need in pruritus treatment. With a market cap of ~$129 million, Tharimmune is positioned as a small-cap biotech with a single lead asset in mid-stage development, carrying typical clinical-stage risks and reliance on successful trial outcomes.

Upcoming Catalysts (preview)

• Q1 2027Phase 2 Interim or Topline Data for Nalmefene in Pruritus Associated with PBC40% success
• TBDPotential Partnership or Licensing Deal for Buccal Film Platform30% success
• Q3 2026Phase 2 Trial Enrollment Completion80% success